FDA
-
-
-
-
-
-
-
Veru completes enrollment in Phase 2b obesity combination drug trial
-
-
-
-
-
-
-
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-
-
-
-
-
-
-
Veru to Report Fiscal Year 2025 Financial Results on December 17th
-
-
-
-
-
-
-
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
-
-
-
-
-
-
-
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th
-
-
-
-
-
-
-
Veru Participates in a Virtual Investor KOL Connect Segment
-
-
-
-
-
-
-
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
330,165 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

